Dov Goldstein is recorded as CFO at BioAge Labs, Inc. (BIOA) and Board Member at Coya Therapeutics, Inc. (COYA) since January 1, 2021. The newest filing on record that lists Dov Goldstein as CFO at BioAge Labs, Inc. (BIOA) is dated April 21, 2026. The newest filing on record that lists Dov Goldstein as Board Member at Coya Therapeutics, Inc. (COYA) is dated May 13, 2026. Dov Goldstein was last confirmed as Board Member at Gain Therapeutics, Inc. (GANX) in a filing dated April 28, 2023. Coya Therapeutics, Inc. reported in an 8-K filed May 8, 2024 that Dov Goldstein was appointed Class II director, effective May 8, 2024. Dov Goldstein has spoken on 3 investor events across 1 company, most recently for BioAge Labs, Inc. on September 9, 2026. BioAge Labs, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Coya Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at BioAge Labs, Inc. includes Kristen Fortney (CEO) and Eric Morgen (COO).
“The election of Anabella Villalobos, Ph.D. and Dov Goldstein, M.D., M.B.A., as Class II directors to hold office for a term of three years, until their successors are duly elected and qualified or they are otherwise unable to complete their respective terms.”
Coya Therapeutics, Inc. Form 8-K, filed May 8, 2024
· Read the filing
Dov Goldstein on recent calls
“If you look at the distribution of the markets, about 40% of the market doesn't get injections. So this is the watchful waiting group. So the physician, it's generally a little bit of edema without vision loss.”
“So as far as partnership, we strongly believe the best way to form a partnership potentially is for the company to be in a strong position to go at ourselves. And that means, as BJ mentioned, preparedness, but also financial preparedness.”
